High resolution imaging for prostate cancer detection
A Comparative Study of High Resolution DWI and Conventional DWI in Prostate
The First Affiliated Hospital with Nanjing Medical University · NCT06636747
This study is testing whether a new type of MRI can find prostate cancer better than the standard MRI to help doctors make more accurate diagnoses.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 55 Years and up |
| Sex | Male |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University (other) |
| Locations | 2 sites (Nanjing, Jiangsu and 1 other locations) |
| Trial ID | NCT06636747 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of high resolution diffusion weighted imaging (hrDWI) compared to conventional diffusion weighted imaging (cDWI) in detecting prostate cancer. The study aims to enhance the diagnostic accuracy of prostate MRI by improving the signal-to-noise and contrast-to-noise ratios, resulting in clearer images that can better differentiate malignant tissues from healthy ones. Participants will undergo standard MRI scans, including hrDWI and cDWI, to assess the quality and effectiveness of these imaging techniques. The ultimate goal is to improve the detection and diagnosis of prostate cancer through advanced imaging methods.
Who should consider this trial
Good fit: Ideal candidates for this study are men who are undergoing standard MRI scans for prostate evaluation and have complete clinical information available.
Not a fit: Patients currently using 5-alpha-reductase inhibitors or those with a history of prostate biopsy, surgery, or treatment for prostate cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses of prostate cancer, allowing for earlier and more effective treatment.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving imaging techniques for cancer detection, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who underwent standard MR scanning including T2WI, cDWI , hrDWI and respective calculated apparent diffusion coefficient (ADC) maps; 2. Complete clinical information. Exclusion Criteria: Men were excluded if they were using 5-alpha-reductase inhibitors at time of examination or has used such during the previous six months; or if they had a previous history of prostatic biopsy, prostatic surgery, or treatment for PCa
Where this trial is running
Nanjing, Jiangsu and 1 other locations
- The First Affiliated Hospital with Nanjing Medical University — Nanjing, Jiangsu, China (RECRUITING)
- Yu-Dong Zhang — Nanjing, China (RECRUITING)
Study contacts
- Principal investigator: Fei-Yun Wu — The First Affiliated Hospital with Nanjing Medical University
- Study coordinator: Yu-Dong Zhang
- Email: njmu_zyd@163.com
- Phone: 86-18251966069
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer, Prostate Disease, diffusion weighted imaging, prostate cancer